Aion Therapeutic Inc (TSE:AION)
:AION
Top Page
No summary available
Positive Factors
Revenue Growth
Aion Therapeutic's significant revenue growth indicates successful market penetration and potential for future expansion in the biotechnology sector.
Negative Factors
High Leverage
Aion's high leverage and negative equity indicate financial instability, which could limit its ability to invest in growth and innovation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Aion Therapeutic's significant revenue growth indicates successful market penetration and potential for future expansion in the biotechnology sector.
Read all positive factors
Aion Therapeutic Inc (AION) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.42M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)-2.33
Revenue Growth563.34%
EPS Growth-68.82%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding483,549,260
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-0.54
Price to Sales (P/S)0.00
P/FCF Ratio-35.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aion Therapeutic Inc Business Overview & Revenue Model
Company Description
Aion Therapeutic Inc. offer medical cannabis products in Canada. The company was formerly known as Osoyoos Cannabis Inc. and changed its name to Aion Therapeutic Inc. in August 2020. Aion Therapeutic Inc. was incorporated in 2011 and is headquarte...
How the Company Makes Money
Aion Therapeutic Inc generates revenue primarily through the development and commercialization of its proprietary therapeutic products. These products are designed to address a range of health conditions using natural compounds. The company's reve...
Aion Therapeutic Inc Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Jul 2023 | Jul 2021 | Apr 2020 | Apr 2019 | Apr 2018 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.47M | 367.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 298.90K | 163.12K | -65.29K | -111.05K | 0.00 | -2.00K |
| EBITDA | -6.19M | -6.07M | -3.68M | -240.59K | -3.44M | -131.08K |
| Net Income | -6.65M | -6.29M | -3.82M | -672.83K | -5.61M | -140.11K |
Balance Sheet | ||||||
| Total Assets | 1.21M | 702.86K | 150.14K | 3.34M | 4.11M | 8.99K |
| Cash, Cash Equivalents and Short-Term Investments | 13.82K | 68.34K | 239.83K | 612.79K | 1.62M | 269.00 |
| Total Debt | 2.81M | 2.08M | 744.06K | 958.91K | 1.18M | 1.45M |
| Total Liabilities | 5.88M | 4.57M | 2.56M | 1.20M | 1.47M | 321.11K |
| Stockholders Equity | -4.67M | -3.87M | -2.41M | 2.13M | 2.64M | -312.13K |
Cash Flow | ||||||
| Free Cash Flow | -1.55M | -845.04K | -2.79M | -756.38K | -3.27M | -332.87K |
| Operating Cash Flow | -1.55M | -845.04K | -1.35M | -551.75K | -1.32M | -332.87K |
| Investing Cash Flow | 0.00 | -289.42K | -1.38M | -333.19K | -2.01M | 14.06K |
| Financing Cash Flow | 1.41M | 1.12M | 1.20M | -125.00K | -286.14K | 317.23K |
Aion Therapeutic Inc Technical Analysis
Positive
0.01
Price Trends
0.01
Negative
0.01
Negative
0.01
Negative
Market Momentum
<0.01
Positive
51.32
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AION, the sentiment is Positive. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.32 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AION.
Aion Therapeutic Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | C$2.42M | -0.64 | ― | ― | 563.34% | -68.82% | |
51 Neutral | C$29.96M | -19.43 | -71.80% | ― | -3.94% | -17.62% | |
50 Neutral | C$56.36M | -2.79 | -19.76% | ― | 26.91% | 81.01% | |
49 Neutral | C$27.35M | -3.68 | -19.10% | ― | 18.06% | 34.58% | |
46 Neutral | C$18.85M | -5.08 | -68.32% | ― | 2.41% | 74.61% |
* Healthcare Sector Average
TSE:AION
Aion Therapeutic Inc
0.01
0.00
0.00%
TSE:ATLE
Willow Biosciences Inc
0.16
0.11
226.53%
TSE:QNTM
Quantum Biopharma
5.60
-3.42
-37.92%
TSE:LABS
MediPharm Labs
0.07
-0.02
-23.53%
TSE:AVCN
Avicanna
0.15
-0.09
-37.50%
TSE:INNO
InnoCan Pharma
6.66
-3.74
-35.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―